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Background. Most tumor-associated antigens (TAA) currently used for immunotherapy of cancer are also expressed in normal
tissues, which may induce tolerance and impair T cell-mediated immunity. However, there is limited information about how
physiological expression in normal tissues alters the function of TAA-specific T cells. Methodology/Principal Findings. We
used a T cell receptor transgenic model to study how MDM2 expression in normal tissues affects the function of T cells specific
for this TAA that is found at high levels in many different types of tumors. We found that some MDM2-specific T cells escaped
thymic deletion and persisted in the peripheral T cell pool. When stimulated with antigen, these T cells readily initiated cell
division but failed to proliferate and expand, which was associated with a high rate of apoptosis. Both IL-2 and IL-15 efficiently
rescued T cell survival and antigen-specific T cell proliferation, while IL-7 and IL-21 were ineffective. Antigen-stimulated T cells
showed impaired expression of the effector molecules CD43, granzyme-B and IFN-c, a defect that was completely restored
when T cells were stimulated in the presence of IL-2. In contrast, IL-15 and IL-21 only restored the expression of CD43 and
granzyme-B, but not IFN-c production. Finally, peptide titration experiments with IL-2 rescued T cells indicated that they were
of lower avidity than non-tolerant control T cells expressing the same TCR. Conclusions/Significance. These data indicate
that cytokines can rescue the antigen-specific proliferation and effector function of MDM2-specific T cells, although this does
not lead to the recovery of high avidity T cell function. This study sheds light on possible limitations of immunotherapy
approaches that target widely expressed TAA, such as MDM2.
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INTRODUCTION
Mechanisms of both central and peripheral tolerance have evolved
to silence T cells with specificity for self-antigen. Whilst these
mechanisms of T cell tolerance reduce the risk of autoimmunity,
they also represent an obstacle to successful T cell-based cancer
immunotherapy, as most T cell-recognised tumor antigens are also
expressed in some normal tissues [1–5]. A better understanding of
the mechanism and the magnitude of tolerance to tumor-
associated antigens (TAAs) will be essential for the rational design
of TAA-specific immunotherapy strategies for the treatment of
cancer. As the antigen expression pattern in normal tissues is likely
to have a major impact on T cell tolerance, it is desirable to
develop models that can provide information on how the
physiological expression of TAAs in normal tissues affects the
development and function of TAA-specific T cells.
In the past T cell receptor (TCR) transgenic models have been
used successfully to provide insights into the mechanisms of central
and peripheral tolerance. Antigen expression in the thymus results
in clonal deletion of developing T cells, although deletion is
sometimes incomplete as T cells can escape into the periphery
[6,7]. For antigens that are expressed outside the thymus, antigen
encounter in the periphery may result in T cell deletion or the
induction of a state of unresponsiveness, often referred to as anergy
[8–11]. Identified mechanisms that can lead to unresponsiveness
include down-regulation of the TCR and accessory molecules such
as CD8 co-receptor, or the disruption of signalling pathways
required for IL-2 production [6,10,12–14]. In addition to deletion
and anergy, ignorance is a form of tolerance where the expression
of antigens in certain immunologically privileged tissues is ignored
by peripheral T cells [15]. Whilst ignorant tolerance is easily
broken by immunization, deletion is irreversible, and strategies for
the reversal of anergy may require some knowledge of the
mechanism and the level of T cell unresponsiveness.
Recently, two transgenic mouse lines expressing TCRs specific
for two defined TAAs have been developed in order to analyse
how TAA expression in normal tissues affects T cell function. In
one model, the TCR was specific for an epitope of gp100, a TAA
that is over-expressed in most melanomas while its physiological
expression is restricted to melanocytes [16]. In another model, the
TCR was specific for an epitope in the gag protein of Friend
Murine Leukaemia Virus (FMuLV), which is a major CTL target
in FMuLV-transformed murine tumors [17]. In this case gag-
transgenic mice were generated to target the expression of this
model TAA to normal liver tissue. The immunological analysis in
these two models revealed a relatively low level of tolerance against
gp100, whilst T cell tolerance against gag was more profound. It is
possible that these difference were due to differences in the
tolerogenic properties of skin melanocytes versus the liver,
although it is also possible that high level of transgene driven
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gag expression may have contributed to a more pronounced T cell
tolerance. Here, we set out to assess tolerance to a TAA that is
naturally expressed in most normal tissues.
MDM2 is over-expressed in a large number of human
malignancies of haematological and epithelial origin [18–23].
The MDM2 oncogene functions by inactivating the p53 tumor
suppressor protein [24,25], and its over-expression in tumors was
shown to contribute to the process of malignant transformation
[18–23]. Using HLA-A2 transgenic mice and the allo-restricted
strategy to circumvent tolerance to MDM2, we have previously
demonstrated that CTL specific for an HLA-A2 presented peptide
can kill a panel of human leukemia cell lines, while MDM2
expression levels in normal cells were too low to trigger CTL
killing [26]. We also observed that CTL with this specificity were
not detectable in HLA-A2 positive humans, which was compatible
with the suggestion that tolerance mechanisms may have
inactivated or deleted such CTL.
As the MDM2 expression pattern in normal tissues is similar in
humans and mice, we generated TCR transgenic mice to study
tolerance mechanisms against this TAA. Previously, we isolated
from H2d BALB/c mice high avidity allo-restricted CTL clones
specific for an MDM2-derived peptide, pMDM100, presented by
H2-Kb class I molecules [27,28]. In this study, the TCR genes
from the CTL were isolated and used to produce transgenic H2d
mice that did not present the TCR recognised pMDM100 peptide
(referred to as Agneg mice), and H2dxb F1 transgenic mice in which
the peptide is presented by normal tissues (referred to as Agpos
mice). These mice enabled us to determine how physiological
MDM2 expression in normal tissues affected the development and
function of T cells specific for this TAA.
We found that some MDM2-specific T cells escaped thymic
deletion and accumulated in the periphery. When stimulated with
antigen, these T cells initiated cell division but failed to expand
and showed poor production of the T cell effector molecules
CD43, granzyme-B and IFN-c. IL-7 and IL-21 did not rescue T
cell expansion, although IL-21 enhanced CD43 and granzyme-B
expression, but not IFN-c production. Both IL-2 and IL-15
restored robust T cell expansion, which correlated with a strong
up-regulation of Bcl-2 expression. Whilst IL-15 only restored
CD43 and granzyme-B production, IL-2 rescued expression of all
effector markers including the production of IFN-c. Therefore, in
terms of expansion and effector differentiation the IL-2-rescued T
cells seemed equivalent to non-tolerant control T cells expressing
the same MDM2-specific TCR. However, peptide titration
experiments revealed that triggering of rescued T cells required
higher peptide concentrations than triggering of non-tolerant
control T cells. Together, the data show that while expansion and
effector differentiation can be efficiently restored by cytokines, the
impaired avidity of the rescued T cells might compromise their
anti-tumor activity.
MATERIALS AND METHODS
Mice
To generate pMDM100 specific TCR transgenic mice the Va5
and Vb7 TCR chain genes from a high avidity allo-MHC-
restricted pMDM100-specific CTL clone [27,28] were cloned into
a CD2-vector (courtesy of Dr D. Kioussis) in preparation for
microinjections into (C57BL/66CBA) F1 (H2bxk) oocytes to
produce transgenic mice. The transgenic mice were produced in
collaboration with Dr M. Mendelson (Columbia University, USA).
The Agneg mice (transgenic H2d mice) used in the experiments
reported here were crossed back with BALB/c mice for at least
five generations. The Agpos mice (transgenic H2dxb F1 mice) used
were generated by mating the Agneg mice with C57BL/6 mice.
Mice were typed for pMDM100-specific TCR expression by
isolation of mouse-tail genomic DNA followed by polymerase
chain reaction (PCR) screening. The oligonucleotide primer
sequences used in the PCR reaction were: the CD2-56 forward
primer (Invitrogen, UK): 59-AACCCAGCTTTCCCTGAAAG-
TG-39; the Vb7-PSP reverse primer (Invitrogen): 59-GCAGAA-
TCCAGAATCAGGGAG-39 or the Va5-PSP reverse primer
(Invitrogen): 59-CACTGTCTCCCTCCCGGACAC-39.
Peptides, Cytokines and Cell Lines
The synthetic peptide pMDM100 (ProImmune, UK) corresponds
to amino acid 100-107 (YAMIYRNL) of the murine MDM2
protein. Synthetic peptide pSV9 (ProImmune, UK) corresponds to
the amino acids (FAPGNYPAL) of the Sendai virus. In a previous
study we have demonstrated that both pMDM100 and pSV-9
bind efficiently to H2-Kb MHC class I molecules [29]. Peptides
were dissolved in PBS to give a concentration of 2mM and stored
at 220uC. Human recombinant IL-2 (Roche), human recombi-
nant IL-15 (R&D Systems), human recombinant IL-7 (R&D
Systems) and murine recombinant IL-21 (R&D Systems) were
added to selected T cell cultures. RMA-S cells (H2b) were derived
from RMA cells by mutagenesis [30]. RMA-S cells are TAP
deficient due to a point mutation in the TAP2 gene and express
low levels of MHC class I molecules compared to RMA cells
[29,31]. MBL-2 cells (H2b) were derived from a Moloney murine
leukaemia virus induced T-cell lymphoma [32].
Flow cytometric analysis
Spleen and lymph nodes (inguinal and lumbar) were harvested
from 6–8 week old Agneg mice and Agpos mice and single cell
suspensions obtained by macerating tissues through a 40 mm nylon
cell strainer. Samples were stained in PBS (1% FCS) with the
appropriate dilution of the relevant mAbs. Propidium iodide
staining cells were excluded from analysis. Samples were acquired
on an LSR2 flow cytometer (BD Biosciences, USA) and analysed
using FACS Diva software. The following mAbs were used for
flow cytometric staining: rat-anti-mouse Vb7 FITC (Serotec, UK),
rat-anti-mouse CD4 FITC, rat-anti-mouse CD8a APC, rat-anti-
mouse CD8a Cy-Chrome 5 (CY-5), rat-anti-mouse Vb7 PE,
hamster-anti-mouse CD69 PE, rat-anti-mouse CD25 PE, rat-anti-
mouse CD62L-FITC, rat-anti-mouse CD44 PE, rat-anti-mouse
CD43 activation-associated glycoform-PE (all BD Biosciences).
To assess apoptosis, CD8+ T cells were isolated from spleno-
cytes using a CD8a isolation kit (Miltenyi Biotec, Germany)
according to the manufacturer’s protocol, stimulated as described,
stained with annexin V and PI (both BD Biosciences) according to
the manufacture’s protocol and then analysed by flow cytometry as
described previously.
For intracellular staining of Granzyme B and Bcl-2, T cells were
permeabilized with BD cytofix/cytoperm kit (BD Biosciences) and
stained with rat-anti-mouse Granzyme B PE mAb (eBioscience) or
hamster-anti-mouse Bcl-2 FITC mAb (BD Biosciences). Specificity
controls were performed using the appropriate isotype mAbs.
Samples were analysed by flow cytometry as described previously.
Proliferation Assays
Antigen specific T cell proliferation was assessed by directly
visualising the division of cells using the fluorescent cytosolic dye,
Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE), or by
the uptake of 3[H]-thymidine. For CSFE labelling of cells,
splencoytes from the transgenic mice were incubated with 3 mM
CFSE (Molecular Probes, UK) for 3 min at 37uC in 1ml of PBS.
T Cell Tolerance to MDM2
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In each well of a 96 well-plate, 26105 CFSE-labelled splenocytes
were stimulated with 16105 irradiated (80 Gy) temperature-
induced RMA-S coated with pMDM100 peptide (10 mM) or an
irrelevant control peptide, pSV9 (10 mM). The appropriate
cultures were supplemented with 10 U/ml IL-2, 10 ng/ml IL-7,
50 ng/ml IL-15 or 50 ng/ml IL-21. Cells were harvested at the
appropriate time point, stained with CD8a and TCR Vb7 mAbs
and subjected to CFSE profiling by flow cytometry on CD8+Vb7+
T cells. The proliferative response of the CTL in response to
limiting concentrations of antigen was assessed in 3[H]-thymidine
incorporation assays. Triplicate cultures were plated for each
different experimental condition. 56104 temperature induced
irradiated (80 Gy) RMA-S cells were plated onto 96-well plates
with wells containing graded concentrations of peptide in medium
and were incubated for 1 hour at 37uC, prior to the addition of
26105 transgenic splenocytes and 10 U/ml IL-2. Cells were
incubated at 37uC in 5% CO2 for 2 days, pulsed with 0.5 mCi
3[H]-thymidine (Amersham, UK) and incubated for a further
24 hours. The cells were harvested using a 96-well plate harvester
(Skatron Instruments, Norway) onto a filter mat and thymidine
incorporation measured by liquid scintillation counting on a b-
counter (Wallac, Finland).
IFN-c assays
To measure antigen specific IFN-c production, splenocytes from
the transgenic mice were stimulated, culture supernatant harvested
and IFN-c measured in an IFN-c ELISA. To compensate for the
lower numbers of CD8+Vb7+ T cells in the spleens of Agpos mice,
IFN-c production was assessed in cultures containing four-fold
excess of splenocytes from Agpos mice compared to splenocytes
from Agneg mice. Triplicate cultures were plated for each different
experimental condition on 96-well round-bottom plates. In each
well 16104 splenocytes from Agneg mice or 46104 splenocytes
from Agpos mice were stimulated with 16104 irradiated (80 Gy)
temperature-induced RMA-S coated with pMDM100 peptide
(10 mM) or an irrelevant control peptide, pSV9. In some experi-
ments, peptides were added directly to the splenocytes of F1 mice.
The appropriate cultures were supplemented with 10 U/ml IL-2,
10 ng/ml IL-7, 50 ng/ml IL-15 or 50 ng/ml IL-21. For peptide
titration the temperature induced irradiated RMA-S cells were
plated onto 96-well plates with wells containing graded concen-
trations of peptide in medium and were incubated for 1 hour at
37uC prior to adding the transgenic splenocytes. After 72 hours,
50 ml culture supernatant was harvested from each well and
murine IFN-c was measured by sandwich ELISA using anti-IFN-c
antibodies (BD Biosciences). The activity in experimental samples
was ascertained using the standard curve of mean absorbance
values (OD) versus the dilution of recombinant IFN-c in the
supernatant.
The functional activity of IL-2 rescued CTL was measured by
intracellular IFN-c staining. Intracellular IFN-c stainings were
performed as previously described[28]. Samples were analysed
using a FACScaliburTM flow cytometer and CELLQuestTM
software.
IL-2 biosssays
To measure antigen specific IL-2 production, splenocytes from the
transgenic mice were stimulated, culture supernatant harvested
and IL-2 measured using IL-2 dependent CTLL cells. The
stimulation phase of the IL-2 assay was performed exactly as the
IFN-c assay. After 72 hours, 50 ml culture supernatant was
harvested, transferred to wells containing CTLL cells (56103)
and incubated for 16–18 hours. The cells were pulsed with 3[H]-
thymidine by adding 1 mCi 3[H]-thymidine to each well and
incubating for a further 12 hours. The activity in experimental
samples was ascertained using the standard curve of cpm versus
the dilution of recombinant IL-2 in the supernatant.
CTL assays
Cytotoxic activity was determined in 4-hour 51chromium-release
assays against MBL-2 tumor cells and RMA-S cells coated with
pMDM100 peptides or MHC class I-binding control peptides as
described [33].
RESULTS
Transgenic T cells are present in the periphery of
Agpos mice
Monoclonal antibodies against CD4, CD8 and Vb7 were used to
identify cells expressing the transgenic TCR b chain (antibodies
against the transgenic TCR a chain were not available). Although
thymic deletion occurred in Agpos mice (data not shown), a sub-
stantial number of T cells was found in the periphery. The staining
profile of the lymph node samples demonstrated a significant
percentage of CD8+ T cells that expressed Vb7 in the Agpos mice
(Figure 1 A), and a similar profile was observed for splenic T cells
(data not shown). The mean fluorescence intensity (MFI) of Vb7
staining for the T cells of Agpos mice was 3075 compared to 5543
in the Agneg control mice (Figure 1A). Similarly, there was a
decrease in the CD8 expression in T cells of Agpos mice compared
to in the Agneg mice (MFI of CD8 staining: 13907 and 32526). The
decreased CD8 expression in the Agpos mice was seen only on the
CD8+ T cells that expressed the transgenic Vb7 TCR but not on
those that did not. These data demonstrated that the MDM2-
specific T cells in the periphery of Agpos mice had down-regulated
CD8 co-receptor and TCR expression.
Next the expression of the activation markers CD25, CD44,
CD62L and CD69 was analysed on lymph node cells from Agpos
and Agneg mice. The T cells from both sets of mice were CD25lo,
CD69lo and CD62Lhi (Figure 1B). While the T cells of Agneg mice
expressed intermediate levels of CD44, which is associated with
a naı¨ve phenotype, the T cells of the Agpos mice were CD44hi,
which is characteristic of antigen experienced T cells (Figure 1 B).
T cells of Agpos mice display defects in antigen-
driven expansion
We then analysed antigen-specific proliferation of the T cells in the
Agpos mice and Agneg mice. Splenocytes from the mice were CFSE
labelled, stimulated in vitro with pMDM100-coated RMA-S cells
followed by staining with antibodies against CD8 and Vb7 to
identify transgenic T cells. The CFSE labelled T cells from the
Agneg mice divided in response to pMDM100 stimulation, with
each cell division producing an increase in the number of viable T
cells containing reduced levels of CFSE (Figure 2A). Whilst the T
cells from the Agpos mice divided a similar number of times in
response to antigen-specific stimulation, we failed to see an
accumulation of the divided T cells (Figure 2 A). CFSE labelled T
cells from the Agneg or Agpos mice stimulated with a H2-Kb
binding control peptide, pSV9, did not proliferate in these CFSE
assays (Figure 2A).
As IL-2 is a major autocrine growth factor produced by
functionally competent CD8+ T cells, we explored if T cells of
Agpos mice were able to express this cytokine. While non-tolerant
control T cells of Agneg mice secreted IL-2 upon peptide
stimulation, no IL-2 was detectable when the T cells of Agpos
mice were stimulated (Figure 2B). Together, this suggested that the
T Cell Tolerance to MDM2
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T cells displayed an anergic phenotype characterised by a lack of
IL-2 production and an inability to expand upon peptide
stimulation. Thus, we sought to determine whether the anergic
T cells displayed regulatory activity and inhibited the proliferation
of functionally competent T cells. To do this, CFSE labelled T
cells from the Agneg mice were co-cultured with unlabelled tolerant
T cells and stimulated with pMDM100 for 72 hours. CFSE-
labelled non-tolerant T cells showed peptide-specific proliferation
regardless of whether or not tolerant T cells were present in the
cultures (Figure 2C). As expected, CFSE-labelled tolerant T cells
showed defective expansion when stimulated with pMDM100
peptides. This defect was reversed when tolerant T cells were
stimulated with peptide in the presence of non-tolerant T cells
(Figure 2D), indicating that functionally competent T cells were
able to restore the expansion of tolerant T cells. As non-tolerant T
cells can produce IL-2 upon peptide stimulation (see above) it is
possible that this cytokine may have triggered the expansion of the
peptide-stimulated tolerant T cells. To explore this further, we
tested directly whether IL-2 or other common gamma chain
cytokines were able to restore the expansion of the tolerant T cells.
IL-2 and IL-15 efficiently induce Bcl-2 expression and
restore the expansion of tolerant T cells
CFSE-labelled T cells of Agpos mice were stimulated with peptide
antigen in the presence of IL-2, IL-7, IL-15 or IL-21. FACS
Figure 1. MDM2-specific CD8+ T cells are present in the periphery of
Agpos mice and express reduced levels of TCR and CD8 but high
levels of CD44. (A) Lymph nodes cells from 6–8 week old Agpos and
Agneg mice were stained with antibodies against CD4, CD8 and Vb7 and
analysed by flow cytometry. Numbers in quadrants are percentage of
live-gated lymphocytes. (B) Lymph node cells were stained with
antibodies against CD8, Vb7 and the activation markers CD44, CD62L,
CD69 and CD25. Histograms display gated viable CD8+Vb7+ cells.
Numbers in histograms represent the specific MFI of the activation
marker staining for the gated population. Data are representative of at
least three independent experiments.
doi:10.1371/journal.pone.0000353.g001
Figure 2. MDM2-specific T cells from Agpos mice display defects in
antigen-driven expansion. (A) CFSE-labelled splenocytes from Agneg
and Agpos mice were stimulated with RMA-S coated with pMDM100
peptide (10 mM) or pSV9 peptide (10 mM) for 48 hrs, stained with CD8
and Vb7 mAbs and subjected to CFSE profiling by flow cytometry of
gated CD8+Vb7+ T cells. Data are representative of at least three
independent experiments. (B) To measure antigen-specific IL-2 pro-
duction, splenocytes from Agneg mice and Agpos mice were stimulated
with RMA-S cells coated with pMDM100 peptide (100 mM) or a control
peptide, pSV9 (100 mM). After 72 hours, 50 ml of culture supernatant
was harvested and murine IL-2 was measured in a CTLL bioassay. Data
represent the mean6SD of triplicate values and are representative of
two independent experiments. (C) CFSE-labelled splenocytes from
Agneg mice were stimulated with RMA-S cells coated with pMDM100 or
SV9 control peptides for 72 hrs. In the bottom panel, CFSE-labelled T
cells were stimulated for 72h with pMDM100 in the presence of
unlabelled splenocytes from Agpos mice. (D) CFSE-labelled splenocytes
from Agpos mice were stimulated with RMA-S cells coated with
pMDM100 or SV9 control peptides for 72 hrs. In the bottom panel,
CFSE-labelled T cells were stimulated for 72h with pMDM100 in the
presence of unlabelled splenocytes from Agneg mice.
doi:10.1371/journal.pone.0000353.g002
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analysis revealed that peptide stimulation in the presence of IL-2
and IL-15 resulted in robust expansion of tolerant T cells
(Figure 3A). The observed kinetics of cell division and cell
accumulation was similar to that seen with peptide-stimulated
non-tolerant control T cells of Agneg mice. In contrast, tolerant T
cells stimulated with peptide and IL-7 or IL-21 showed a defect in
the accumulation of divided cells similar to that seen after peptide
stimulation without cytokines (Figure 3A). This indicated that IL-7
and IL-21 were unable to rescue the defective expansion of
tolerant T cells.
Next, we explored whether IL-2, IL-7, IL-15 or IL-21 enhanced
the expression of the anti-apoptotic molecule Bcl-2 in tolerant T
cells. Peptide stimulation in the absence of cytokines revealed that
the tolerant T cells expressed substantially less Bcl-2 than the non-
tolerant control T cells (Figure 3B). However, stimulation in the
presence of IL-15 and IL-2 resulted in higher levels of Bcl-2
expression in tolerant T cells compared to the control T cells.
Although IL-7 and IL-21 were able to up-regulate Bcl-2 expression
in tolerant T cells, the levels were lower than those seen after IL-2
and IL-15 stimulation. These data showed that the efficient Bcl-2
up-regulation seen with IL-2 and IL-15 correlated with the ability
of these cytokines to rescue the expansion of tolerant T cells.
Further experiments revealed that the defective expansion of
tolerant T cells correlated with a high rate of apoptosis as revealed
by annexin-V and propidium iodide staining (Figure 3C). When
tolerant T cells were stimulated in the presence of IL-2 they
showed a low level of apoptosis similar to that seen in non-tolerant
control T cells. Thus, it is possible that up-regulation of Bcl-2
resulted in the suppression of apoptosis which promoted the
expansion of the tolerant T cells. Alternatively, it is possible that
IL-2 and IL-15 activated additional pathways required for T cell
expansion, and that these pathways were not activated by IL-7 and
IL-21.
Rescue of defective effector differentiation of
tolerant T cells
We then analysed the effect of the common gamma chain
cytokines on the differentiation of tolerant lymphocytes into
effector T cells. We measured IFN-c secretion as this effector
molecule is typically produced by CD8+ T cells. We also measured
expression of the serine protease granzyme-B as it plays a key role
Figure 3. IL-2 and IL-15 efficiently induce Bcl-2 expression and restore the expansion of tolerant MDM2-specific CD8+ T cells. (A) CFSE-labelled
splenocytes from Agneg and Agpos mice stimulated with RMA-S coated with pMDM100 peptide (10 mM) for 72 hrs in the presence of 10 U/ml IL-2,
10 ng/ml IL-7, 50 ng/ml IL-15 or 50 ng/ml IL-21, stained with CD8 and Vb7 mAbs and subjected to CFSE profiling of gated CD8+Vb7+ T cells. (B)
Splenocytes from Agneg mice and Agpos mice were stimulated for 3 days in vitro with pMDM100-coated targets in the presence of 10 U/ml IL-2,
10 ng/ml IL-7, 50 ng/ml IL-15 or 50 ng/ml IL-21 and Bcl-2 expression levels were analysed by intracellular staining and flow cytometric analysis.
Numbers in histograms represent the specific MFI of the gated CD8+Vb7+ population. Following staining of the splenocytes with an appropriate
isotype control mAb the MFI of the gated CD8+Vb7+ population from the Agneg mice and Agpos mice was 98 and 97, respectively. Data in A and B are
representative of three independent experiments. (C) CD8+ T cells isolated from the spleens of Agneg and Agpos mice were stimulated with RMA-S
coated with pMDM100 peptide (10 mM) in the presence or absence of 10 U/ml IL-2 and cell death was determined on the indicated days by staining
with annexin-V and propidium iodide and flow cytometric analysis.
doi:10.1371/journal.pone.0000353.g003
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in the granule-exocytosis pathway of CTL mediated target cell
killing [34,35]. Finally, we analysed the expression of the
activation-associated glycoform of CD43 which has been shown
to be up-regulated on effector T cells [36].
Upon peptide stimulation in the absence of cytokines, the
tolerant T cells expressed lower levels of CD43 than non-tolerant
control T cells. Stimulation of tolerant T cells in the presence of
IL-7 resulted in a modest CD43 up-regulation. Both IL-15 and
IL-21 triggered more substantial CD43 expression than IL-7,
although the highest CD43 levels were induced by IL-2
(Figure 4A). Interestingly, IL-2 had only a modest effect on
CD43 expression in non-tolerant control T cells, where IL-21
mediated the strongest CD43 up-regulation (Figure 4A).
The granzyme-B expression pattern of tolerant T cells was
similar to that of CD43. Peptide stimulation in the absence of
cytokines resulted in reduced granzyme-B expression in tolerant T
cells compared to non-tolerant control T cells (Figure 4B). IL-2
was most effective in up-regulating granzyme-B expression,
followed closely by IL-21 and IL-15, while IL-7 had only a modest
effect. Finally, the granzyme-B expression pattern correlated with
the cytotoxic activity of tolerant T cells. T cells rescued by IL-2,
IL-15 and IL-21 killed peptide coated target cells and tumor cells
more efficiently than T cells cultured with IL-7 or without cytokine
supplementation (Figure 4C).
The analysis of the effector molecule IFN-c revealed that
tolerant T cells were unable to secrete IFN-c after peptide stimula-
tion in the absence of cytokine, whereas non-tolerant control T
cells readily produced IFN-c (Figure 5A). Whilst IL-2 efficiently
restored IFN-c secretion by tolerant T cells, the other common
gamma cytokines IL-7, IL-15 and IL-21 were unable to promote
IFN-c production (Figure 5B).
Taken together, IL-2 was most effective in restoring all analysed
defects of effector differentiation of tolerant T cells. The activity of
IL-2 was similar to that of IL-15 and IL-21, except that the latter
two cytokines only rescued CD43 and granzyme-B expression but
were unable to restore IFN-c production by tolerant T cells.
Subsequently we tested whether cytokine rescued T cells
became functionally equivalent to non-tolerant T cells, or whether
Figure 4. CTL from Agpos mice display defects at the level of cytotoxic effector function that can most effectively be rescued by IL-2. Splenocytes
from Agneg mice and Agpos mice were stimulated for 3 days in vitro with pMDM100-coated targets in the presence of 10 U/ml IL-2, 10 ng/ml IL-7,
50 ng/ml IL-15 or 50 ng/ml IL-21. (A) CD43 expression levels on the stimulated T cells was analysed by surface staining and flow cytometric analysis.
Numbers in histograms represent the specific MFI of the gated CD8+Vb7+ population. (B) Granzyme B expression levels on the stimulated T cells was
analysed by intracellular staining and flow cytometric analysis. Numbers in histograms represent the specific MFI of the gated CD8+Vb7+ population.
Following staining with an appropriate isotype control mAb the MFI of the gated CD8+Vb7+ T cells from the Agneg mice and Agpos mice was 398 and
495, respectively. Data in A and B are representative of three independent experiments. (C) Cytolytic activity of stimulated T cells against MDM2-
expressing MBL-2 tumor cells and RMA-S targets coated with pMDM100 peptide (10 mM) or a class I binding control peptide, pSV9 (10 mM). Data are
representative of two independent experiments.
doi:10.1371/journal.pone.0000353.g004
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they remained cytokine dependent upon secondary peptide
stimulation. Thus, tolerant T cells were first stimulated with
peptide and IL-2 for 7 days, washed and re-stimulated with
peptide in the absence or presence of IL-2. Secondary stimulation
in the absence of cytokines resulted in poor IFN-c production by
tolerant T cells (5% positive T cells versus 2% background with
the control peptide), whereas re-stimulation in the presence of IL-2
restored IFN-c production by 33% of the T cells (Figure 5C). As
expected, the secondary IFN-c response of non-tolerant control T
cells did not require the presence of IL-2. Peptide stimulation in
the absence of IL-2 supplementation resulted in IFN-c production
by 23% of T cells, which increased to approximately 42% in the
presence of IL-2. Together, these experiments indicated that IL-2
rescued tolerant T cells remained IL-2-dependent when re-
challenged with peptide antigen.
The cytokine rescued tolerant T cells display
reduced functional avidity
As IL-2 rescued tolerant T cells seemed functionally equivalent to
the non-tolerant control T cells we assessed the avidity of these two
T cell populations. IL-2 rescued T cells and control T cells were
stimulated with decreasing concentrations of peptide followed by
measurement of IFN-c production. IL-2 rescued T cells required
higher peptide concentrations to trigger IFN-c production than
non-tolerant control T cells (Figure 6A). Similarly, antigen-specific
proliferation required higher peptide concentrations when IL-2
rescued tolerant T cells were compared with non-tolerant control
T cells (Figure 6B). Therefore, despite expressing the same trans-
genic TCR, the cytokine rescued T cells were of lower functional
avidity than the non-tolerant control T cells.
DISCUSSION
In this study we defined how physiological expression of the
endogenous MDM2 protein shapes the response profile of T cells
expressing an MDM2-specific TCR. The peripheral T cells
responded to MDM2 peptides by initiating cell division, but the
cells were unable to expand which correlated with a block in IL-2
production. This resembled the phenotype of the CD8+ T cells
from protein kinase C-h (PKCh)-deficient mice [37]. CD8+ T cells
in PKCh-deficient mice underwent antigen-induced proliferation
Figure 5. pMDM100-specific CD8+ T cells from Agpos mice display defects in IFN-c effector function that can be restored by IL-2. (A) To measure
antigen-specific IFN-c production, splenocytes from Agpos mice and Agneg mice were stimulated with RMA-S cells coated with pMDM100 peptide
(10 mM) or a control peptide, pSV9 (10 mM). After 72 hours, 50 ml of culture supernatant was harvested and IFN-c was measured by ELISA. Data
represent the mean6SD of triplicate values. (B) Antigen-specific IFN-c production by splenocytes from Agpos mice stimulated with pMDM100 peptide
or a control pSV9 peptide in the presence of 10 U/ml IL-2, 10 ng/ml IL-7, 50 ng/ml IL-15 or 50 ng/ml IL-21. After 72 hours, 50 ml of culture
supernatant was harvested and IFN-c was measured by ELISA. Data represent the mean6SD of triplicate values. Data in A and B are representative of
three independent experiments. (C) Antigen-specific IFN-c production upon secondary peptide stimulation of IL-2 rescued T cells was measured by
intracellular staining for IFN-c. T cells were re-stimulated with RMA-S cells coated with pMDM100 (10 mM) or an irrelevant control peptide, pSV9
(10 mM), for 5 hours in the presence or absence of 10 U/ml IL-2, followed by intracellular staining for IFN-c. Comparable results were obtained when
IFN-c production by IL-2 rescued T cells was measured by ELISA in two independent experiments.
doi:10.1371/journal.pone.0000353.g005
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but displayed impaired survival and therefore failed to accumulate.
Exogenous IL-2 or culture with wild-type T cells could correct the
defective expansion of the PKCh-deficient T cells, which is similar
to the observations with the tolerant T cells analysed in this study.
Therefore, it is tempting to speculate that a defect in the PKCh
pathway may underlie the defective expansion of the MDM2-
specific T cells from Agpos mice.
We found that IL-2 was able to rescue the expansion and
effector differentiation, including IFN-c production, of tolerant T
cells. Surprisingly, IL-15 was unable to rescue IFN-c production
by the tolerant MDM2-specific T cells. As previous studies have
demonstrated that IL-15 stimulation can promote IFN-c pro-
duction by murine and human T cells [38,39], this pathway seems
to be defective in the tolerant T cells studied here. The observation
that IL-15 stimulation enhanced T cell expansion and expression
of certain effector markers indicated that the tolerant T cells were
responsive to IL-15, but retained a selective defect in the pathway
leading to IFN-c expression. Furthermore, the differential effects of
IL-2 and IL-15 in tolerant T cells indicated that these two
common gamma chain cytokines use distinct mechanisms to
trigger the production of IFN-c. Whilst previous studies have
identified a transcriptional control mechanism by which IL-2
induced IFNc expression [40], the mechanism of IL-15-mediated
IFN-c production is currently less clear.
IL-21 was unable to rescue the expansion of the tolerant T cells,
but was able to up-regulate the expression of CD43 and
granzyme-B. Like IL-15, IL-21 did not promote IFN-c production
of peptide-stimulated tolerant T cells. Recent studies have shown
that IL-21 can work synergistically with IL-15 to promote
expansion and effector differentiation of naı¨ve T cells in mice
and in humans [38,41]. It will be interesting to study how
combinations of common gamma chain cytokines affect the
function of the MDM2-specific T cells. A major advantage of IL-
15 and IL-21 is that they can maintain the expression of the T cell
co-stimulatory molecule CD28 and lymphoid homing markers
such as CD62L [38], which was found to improved the in vivo
survival and anti-tumor activity of adoptively transferred T cells in
murine model experiments [39,41,42].
Recent studies analysed T cell tolerance of transgenic T cells
expressing TCRs specific for the murine homologue of the
melanoma antigen gp100 and the gag protein of FMuLV [16,17].
The gp100-specific T cells seemed little affected by antigen
expression in normal melanocytes, as they were functionally
competent when stimulated with peptides ex vivo [16]. In contrast,
the peptide stimulation of the gag-specific T cells showed that they
were unable to proliferate, although they developed cytotoxicity
and produced IFN-c. IL-2 was relatively inefficient in reversing the
proliferative defect of the gag-specific CTL, while IL-15 was highly
effective in this model [17,43]. The analysis of MDM2-specific
CTL showed that both IL-2 and IL-15 restored T cell proliferation
and expansion, indicating differences in the mechanism of
tolerance induced by gag and MDM2. It is likely that the tissue-
specificity and level of antigen expression determined the level of
tolerance in the three transgenic models. The gp100 expression in
melanocytes had little effect on T cell function, MDM2 expression
in most normal tissues induced tolerance that was readily reversed
by IL-2, whilst the expression of gag as a transgene using the
albumin promoter rendered tolerant T cells relatively unrespon-
sive to IL-2. Together, these TCR transgenic models provide
valuable information about how distinct expression patterns in
normal tissues affects the state of tolerance of TAA-specific T cells.
Furthermore, these models can be used to gain insights into
possible strategies to reverse tolerance of TAA-specific CTL.
We found that IL-2 was effective in restoring the function of
MDM2-specific T cells ex vivo, although this did not lead to
a complete restoration of T cell avidity. A possible explanation for
the lower avidity of rescued T cells is the reduced expression levels
of the TCR and the CD8 co-receptor seen in the tolerant T cells.
It is interesting to note that MDM2 presentation in Agpos mice was
sufficient to trigger TCR down-regulation, although previous
studies suggested that effector CTL did not recognise normal
tissues. For example, high avidity effector CTL specific for the
same MDM2 peptide analysed here, selectively killed MDM2
expressing tumors but not normal cells [27,28]. These observa-
tions suggested, that the antigen threshold required for the
induction of tolerance in the transgenic T cells was lower that the
threshold required for the triggering of cytotoxic effector CTL.
However, it is possible that effector CTL remain susceptible to the
tolerogenic signals that diminish the function of the tolerant T
cells. We observed that adoptive transfer of MDM2-specific
effector CTL into tumor-bearing resulted in the induction of T cell
unresponsiveness [28]. This unresponsiveness was not due to
tumor induced immune suppression, but was also seen after CTL
transfer into tumor free animals. This is compatible with the idea
that antigen expression in normal tissues can induce tolerance in
Figure 6. pMDM100-specific CD8+ T cells from Agpos mice display
reduced functional avidity. (A) Splenocytes from Agneg mice and Agpos
mice were stimulated with RMA-S cells coated with titrated concentra-
tions of pMDM100 peptide or an irrelevant control peptide, pSV9, in the
presence of 10 U/ml IL-2. After 72 hours, 50 ml of culture supernatant
was harvested and IFN-c was measured by ELISA. Data represent
mean6SD of triplicate values. IFN-c produced in response to RMA-S
loaded with pSV9 was subtracted from all values. Data are represen-
tative of two independent experiments. (B) To measure antigen specific
proliferation, splenocytes from Agneg mice (black squares) and Agpos
mice (grey circles) were stimulated with RMA-S cells coated with titrated
concentrations of pMDM100 peptide or an irrelevant control peptide,
pSV9, in the presence of 10 U/ml IL-2 for 2 days, and then pulsed with
0.5 mCi 3[H]-thymidine for 24 hours. The maximal proliferative response
by splenocytes from the Agneg and Agpos mice was 130480.269552.9
CPM and 56225.1762794.9 CPM (triplicate values), respectively.
doi:10.1371/journal.pone.0000353.g006
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adoptively transferred CTL, even when antigen levels are
insufficient to trigger effector function. Thus, it is likely that
adoptive T cell therapy needs to be combined with strategies that
can protect transferred T cells from the induction of unrespon-
siveness. One of the beneficial effects of IL-2, which is typically
administered in combination with adoptive T cell transfer
[16,43,44], may relate to its ability to prevent anergy induction
in transferred T cells.
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